AR059355A1 - Inhibidores de 11-beta hsd1 - Google Patents
Inhibidores de 11-beta hsd1Info
- Publication number
- AR059355A1 AR059355A1 ARP070100510A ARP070100510A AR059355A1 AR 059355 A1 AR059355 A1 AR 059355A1 AR P070100510 A ARP070100510 A AR P070100510A AR P070100510 A ARP070100510 A AR P070100510A AR 059355 A1 AR059355 A1 AR 059355A1
- Authority
- AR
- Argentina
- Prior art keywords
- atoms
- optionally substituted
- nrdre
- srg
- thioaryloxy
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
- C07D211/92—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with a hetero atom directly attached to the ring nitrogen atom
- C07D211/96—Sulfur atom
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D295/00—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms
- C07D295/22—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with hetero atoms directly attached to ring nitrogen atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D295/00—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms
- C07D295/22—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with hetero atoms directly attached to ring nitrogen atoms
- C07D295/26—Sulfur atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
- C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Diabetes (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Biomedical Technology (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Cardiology (AREA)
- Dermatology (AREA)
- Heart & Thoracic Surgery (AREA)
- Child & Adolescent Psychology (AREA)
- Vascular Medicine (AREA)
- Hospice & Palliative Care (AREA)
- Urology & Nephrology (AREA)
- Emergency Medicine (AREA)
- Psychiatry (AREA)
- Endocrinology (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Hydrogenated Pyridines (AREA)
- Pyridine Compounds (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
- Steroid Compounds (AREA)
Abstract
Compuestos, composiciones farmacéuticas y métodos para tratar enfermedades mediada por exceso de cortisol, para tratar diabetes tipo 2, hiperlipidemia, desordenes cognitivos entre otras. Reivindicacion 1:Un compuesto que posee la formula (1) caracterizado porque: R1 es:(i) arilo C6-18 o heteroarilo que incluye de 5-20 átomos, cada uno de los cuales está opcionalmente substituido con desde 1 a 10 Ra; o (ii) aralquilo C7-20, heteroaralquilo que incluye de 6-20 átomos; arilheterociclilo que incluye de 8-20 átomos; arilcicloalquenilo que incluye de 8-20 átomos, o arilheterocicloalquenilo que incluye de 8-20 átomos; cada uno de los cuales está opcionalmente substituidos con desde 1 a 10 Rb; R2 es arilo C6-18 o heteroarilo que incluye de 5-20 átomos, cada uno de los cuales está opcionalmente substituido con desde 1 a 10 Rc; X es S(O)n o S(O)nNR6, donde n es 1 o 2, y R6 es hidrogeno, alquilo C1-12, o cicloalquilo C3-16, cada uno de V e Y es, independientemente, CR7 o N, donde R7 es hidrogeno o alquilo C1-12, con tal que Y y V no pueden ser ambos CR7, uno, dos, tres, o cuatro de W1, Z1, W2, y Z2 son cada uno, independientemente: (i) alquilo C1-12 o (ii) oxo; o (iii) arilo C6-18 o heteroarilo que incluye de 5-20 átomos, cada uno de los cuales está opcionalmente substituido con desde 1 a 10 Ra; o (iv) aralquilo C7-20, cicloalquilo C3-16, heteroaralquilo que incluye de 6-20 átomos; cicloalquenilo C3-16, heterociclilo que incluye de 3-16 átomos; o heterocicloalquenilo que incluye de 3-16 átomos; cada uno de los cuales está opcionalmente substituido con desde 1 a 10 Rb; y los otros son hidrogeno; Ra cada vez que está presente es, independientemente: (i) halogeno; NRdRe; nitro; azido; hidroxi; alcoxi C1-12 o tioalcoxi C1-12, cada uno de los cuales está opcionalmente substituido con 1-5 Rf; haloalcoxi C1-12, ariloxi C6-16, tioariloxi C6-16, heteroariloxi que incluye de 5-20 átomos, o tioariloxi que incluye de 5-20 átomos, cada uno de los cuales está opcionalmente substituido con 1-5 Ra'; alqueniloxi C2-12, alquiniloxi C2-12, cicloalquiloxi C3-16, cicloalqueniloxi C3-16, heterocicliloxo que incluye de 3-16 átomos, heterocicloalqueniloxi que incluye de 3-16 átomos, aralcoxi C7-20, o heteroaralcoxi que incluye de 6-20 átomos, cada uno de los cuales está opcionalmente substituido con 1-5 Rb; mercapto; ciano; -C(O)Rg, -C(O)ORg, -OC(O)Rg, -C(O)SRg, -SC(O)Rg, -C(S)SRg; -SC(S)Rg, -C(O)NRdRe, -NRhC(O)Ri, -OC(O)NRdRe; o 2 Ra juntos forman alquilendioxi C1-3; (ii) alquilo C1-12 o haloalquilo C1-12, cada uno de los cuales está opcionalmente substituido con desde 1 a 5 Rj, o (iii) aralquilo C7-20, cicloalquilo C3-16, heteroaralquilo que incluye de 6-20 átomos; cicloalquenilo C3-16; heterociclilo que incluye de 3-16 átomos; o heterocicloalquenilo que incluye de 3-16 átomos; cada uno de los cuales está opcionalmente substituido con desde 1 a 10 Rb; o (iv) alquenilo C2-20 o alquinilo C2-20 o (v) arilo C6-16 o heteroarilo que incluye de 5-16 átomos, cada uno de los cuales está opcionalmente substituido con de 1-10 Ra'; Ra' cada vez que está presente es, independientemente, alquilo C1-12, haloalquilo C1-12, alquenilo C2-12, alquinilo C2-12, cicloalquilo C3-16, cicloalquenilo C3-16, heterociclilo que incluye de 3-16 átomos, heterocicloalquenilo que incluye de 3-16 átomos; aralquilo C7-20, arilo C6-16, heteroarilo que incluye de 5-16 átomos; halogeno; NRdRe; nitro; azido, hidroxi; alcoxi C1-12, tioalcoxi C1-12, haloalcoxi C1-12, ariloxi C6-16, tioariloxi C6-16, heteroariloxi que incluye de 5-20 átomos; tioariloxi que incluye de 5-20 átomos; alqueniloxi C2-12, alquiniloxi C2-12, cicloalquiloxi C3-16, cicloalqueniloxi C3-16, heterocicliloxi que incluye de 3-16 átomos; heterocicloalqueniloxi que incluye de 3-16 átomos; aralcoxi C7-20, heteroaralcoxi que incluye de 6-20 átomos; mercapto; ciano; -C(O)Rg, -C(O)ORg, -OC(O)Rg, -C(O)SRg, -SC(O)Rg, -C(S)SRg; -SC(S)Rg, -C(O)NRdRe, -NRhC(O)Ri, -OC(O)NRdRe; o 2 Ra' juntos forman alquilendioxi C1-3; Rb cada vez que está presente es, independientemente: (i) halogeno; NRdRe; nitro; azido; hidroxi; oxo, tioxo, =NRk, alcoxi C1-12 o tioalcoxi C1-12, cada uno de los cuales está opcionalmente substituido con 1-5 Rf, haloalcoxi C1-12, ariloxi C6-16, tioariloxi C6-16, heteroariloxi que incluye de 5-20 átomos, o tioariloxi que incluye de 5-20 átomos, cada uno de los cuales está opcionalmente substituido con 1-5 Ra, alqueniloxi C2-12, alquiniloxi C2-12, cicloalquiloxi C3-16, cicloalqueniloxi C3-16, heterocicliloxi que incluye de 3-16 átomos, heterocicloalqueniloxi que incluye de 3-16 átomos, aralcoxi C7-20, o heteroaralcoxi que incluye de 6-20 átomos, cada uno de los cuales está opcionalmente substituido con 1-5 Rb'; mercapto; ciano; -C(O)Rg, C(O)ORg, -OC(O)Rg, -C(O)SRg, -SC(O)Rg, -C(S)SRg; -SC(S)Rg, -C(O)NRdRe, -NRhC(O)Ri, -OC(O)NRdRe; o 2 Rb juntos forman alquilendioxi C1-3; o (ii) alquilo C1-12 o haloalquilo C1-12, cada uno de los cuales está opcionalmente substituido con desde 1 a 5 Rj, o (iii) aralquilo C7-20, cicloalquilo C3-16, heteroaralquilo que incluye de 6-20 átomos; cicloalquenilo C3-16, heterociclilo que incluye de 3-16 átomos; o heterocicloalquenilo que incluye de 3-16 átomos; cada uno de los cuales está opcionalmente substituido con desde 1 a 10 Rb'; o (iv) alquenilo C2-20 o alquinilo C2-20 o (v) arilo C6-16 o heteroarilo que incluye de 5-16 átomos, cada uno de los cuales está opcionalmente substituido con de 1-10 Ra; Rb' cada vez que está presente es, independientemente, alquilo C1-12 o haloalquilo C1-12, cada uno de los cuales está opcionalmente substituido con 1-5 Rj, alquenilo C2-12, alquinilo C2-12, cicloalquilo C3-16, cicloalquenilo C3-16, heterociclilo que incluye de 3-16 átomos, heterocicloalquenilo que incluye de 3-16 átomos; aralquilo C7-20, arilo C6-16, heteroarilo que incluye de 5-16 átomos; halo; NRdRe; nitro; azido, hidroxi; oxo, tioxo, =NRk, alcoxi C1-12, tioalcoxi C1-12, haloalcoxi C1-12, ariloxi C6-16, tioariloxi C6-16, heteroariloxi que incluye de 5-20 átomos; tioariloxi que incluye de 5-20 átomos; alqueniloxi C2-12, alquiniloxi C2-12, cicloalquiloxi C3-16, cicloalqueniloxi C3-16, heterocicliloxi que incluye de 3- 16 átomos; heterocicloalqueniloxi que incluye de 3-16 átomos; aralcoxi C7-20, heteroaralcoxi que incluye de 6-20 átomos; mercapto; ciano; -C(O)Rg, -C(O)ORg, -OC(O)Rg, -C(O)SRg, -SC(O)Rg, -C(S)SRg; -SC(S)Rg, -C(O)NRdRe, -NRhC(O)Ri o -OC(O)NRdRe; o 2 Rb' juntos forman alquilendioxi C1-3; Rc cada vez que está presente es, independientemente: (i) halogeno; nitro; hidroxi; alcoxi C1-12 opcionalmente substituido con 1-5 Rf, haloalcoxi C1-12, ciano; SO2Rm; o 2 Rc juntos forman alquilendioxi C1-3 o (ii) alquilo C1-12, o haloalquilo C1-12, cada uno de los cuales está opcionalmente substituido con desde 1 a 5 Rj, o (iii) aralquilo C7-20, cicloalquilo C3-16, heteroaralquilo que incluye de 6-20 átomos; cicloalquenilo C3-16, heterociclilo que incluye de 3-16 átomos; o heterocicloalquenilo que incluye de 3-16 átomos; cada uno de los cuales está opcionalmente substituido con desde 1 a 10 Rb, o (iv) alquenilo C2-20 o alquinilo C2-20, o (v) arilo C6-16 o heteroarilo que incluye de 5-16 átomos, cada uno de los cuales está opcionalmente substituido con desde 1 a 10 Ra, cada uno de Rd, Re, Rg, Rh, y Rk, cada vez que están presentes son, independientemente: (i) H; o (ii) alquilo C1-12 o haloalquilo C1-12; cada uno de los cuales está opcionalmente substituido con desde 1 a 5 Rj; o (iii) aralquilo C7-20, cicloalquilo C3-16, heteroaralquilo que incluye de 6-20 átomos; cicloalquenilo C3-16, heterociclilo que incluye de 3-16 átomos, o heterocicloalquenilo que incluye de 3-16 átomos; cada uno de los cuales está opcionalmente substituido con desde 1 a 10 Rb; o (iv) alquenilo C2-20 o alquinilo C2-20; o (v) arilo C6-16 o heteroarilo que incluye de 5-16 átomos, cada uno de los cuales está opcionalmente substituido con desde 1 a 10 Ra; Rf es NRdRe; nitro; azido; hidroxi; oxo, tioxo, =NRk, alcoxi C1-12 o tioalcoxi C1-12, cada uno de los cuales está opcionalmente substituido con 1-5 Rf, haloalcoxi C1-12, ariloxi C6-16, tioariloxi C6-16, heteroariloxi que incluye de 5-20 átomos, o tioariloxi que incluye de 5-20 átomos, cada uno de los cuales está opcionalmente substituido con 1-5 Ra'; alqueniloxi C2-12, alquiniloxi C2-12, cicloalquiloxi C3-16, cicloalqueniloxi C3-16, heterocicliloxi que incluye de 3-16 átomos, heterocicloalqueniloxi que incluye de 3-16 átomos, aralcoxi C7-20, o heteroaralcoxi que incluye de 6-20 átomos, cada uno de los cuales está opcionalmente substituido con 1-5 Rb; mercapto; ciano; -C(O)Rg, -OC(O)Rg, -C(O)SRg, -SC(O)Rg, -C(S)SRg; - SC(S)Rg, -C(O)NRdRe, -NRhC(O)Ri, -OC(O)NRdRe; Ri es Rg; ORg, o NRdRe; Rj es NRdRe; nitro; azido; hidroxi; oxo; tioxo; =NRk, alcoxi C1-12 o tioalcoxi C1-12, cada uno de los cuales está opcionalmente substituido con 1-5 Rf, haloalcoxi C1-12, ariloxi C6-16, tioariloxi C6-16, heteroariloxi que incluye de 5-20 átomos, o tioariloxi que incluye de 5-20 átomos, cada uno de los cuales está opcionalmente substituido con 1-5 Ra'; alqueniloxi C2-12, alquiniloxi C2-12, cicloalquiloxi C3-16, cicloalqueniloxi C3-16, heterocicliloxi que incluye de 3-16 átomos, heterocicloalqueniloxi que incluye de 3-16 átomos, aralcoxi C7-20, o heteroaralcoxi que incluye de 6-20 átomos, cada uno de los cuales está opcionalmente substituido con 1-5 Rb; mercapto; ciano; alquilendioxi C1-3, -C(O)Rg, -C(O)ORg, -OC(O)Rg, -C(O)SRg, -SC(O)Rg, -C(S)SRg; -SC(S)Rg, -C(O)NRdRe, -NRhC(O)Ri, -OC(O)NRdRe; Rm es (i) alquilo C1-12 o haloalquilo C1-12 cada uno de los cuales está opcionalmente substituido con desde 1 a 5 Rj o (ii) aralquilo C7-20, cicloalquilo C3-16, heteroaralquilo que incluye de 6-20 átomos; cicloalquenilo C3-16, heterociclilo que incluye de 3-16 átomos; o heterocicloalquenilo que incluye de 3-16 átomos; cada uno de los cuales está opcionalmente substituido con desde 1 a 10 Rb; o (iii) arilo C6-16 o heteroarilo que incluye de 5-16 átomos, cada uno de los cuales está opcionalmente substituido co
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US77126206P | 2006-02-07 | 2006-02-07 |
Publications (1)
Publication Number | Publication Date |
---|---|
AR059355A1 true AR059355A1 (es) | 2008-03-26 |
Family
ID=38236242
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
ARP070100510A AR059355A1 (es) | 2006-02-07 | 2007-02-07 | Inhibidores de 11-beta hsd1 |
Country Status (18)
Country | Link |
---|---|
US (2) | US7632838B2 (es) |
EP (1) | EP1981848A2 (es) |
JP (1) | JP2009526059A (es) |
KR (1) | KR20080093072A (es) |
CN (1) | CN101400653A (es) |
AR (1) | AR059355A1 (es) |
AU (1) | AU2007212429A1 (es) |
BR (1) | BRPI0707537A2 (es) |
CA (1) | CA2641609A1 (es) |
CR (1) | CR10186A (es) |
GT (1) | GT200800151A (es) |
IL (1) | IL193157A0 (es) |
NO (1) | NO20083492L (es) |
PA (1) | PA8713501A1 (es) |
PE (1) | PE20071232A1 (es) |
RU (1) | RU2008132333A (es) |
TW (1) | TW200800898A (es) |
WO (1) | WO2007092435A2 (es) |
Families Citing this family (44)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP2004619A1 (en) * | 2006-03-23 | 2008-12-24 | Amgen Inc. | 1-phenylsulfonyl-diaza heterocyclic amide compounds and their uses as modulators of hydroxsteroid dehydrogenases |
WO2007135427A1 (en) * | 2006-05-23 | 2007-11-29 | Astrazeneca Ab | 1,4-disubstituted piperazine and 1,4-disubstituted azepane as 11 -beta-hydroxysteroid dehydrogenase 1 inhibitors |
CL2007003223A1 (es) * | 2006-11-10 | 2008-01-11 | Wyeth Corp | Compuestos derivados de piperidinil 4-arilsulfonamidas n-sustituidas, que actuan como moduladores de la proteina sfrp-1; proceso para preparar los compuestos; co mposicion farmaceutica que comprende a dichos copmpuestos y uso de los compuestos para preparar medicamentos para el tratamiento de enfermedades. |
JP2010518109A (ja) * | 2007-02-07 | 2010-05-27 | ワイス エルエルシー | ハロゲン化アミンの製造法 |
EP2025674A1 (de) | 2007-08-15 | 2009-02-18 | sanofi-aventis | Substituierte Tetrahydronaphthaline, Verfahren zu ihrer Herstellung und ihre Verwendung als Arzneimittel |
EP2197873B1 (en) | 2007-09-20 | 2014-07-16 | Irm Llc | Compounds and compositions as modulators of gpr119 activity |
JP5374377B2 (ja) * | 2007-10-18 | 2013-12-25 | 武田薬品工業株式会社 | 複素環化合物 |
CN101597278B (zh) | 2008-06-04 | 2013-04-17 | 中国中化股份有限公司 | 酰胺类化合物及其制备与应用 |
GB0818241D0 (en) * | 2008-10-06 | 2008-11-12 | Cancer Res Technology | Compounds and their use |
AR074318A1 (es) | 2008-11-14 | 2011-01-05 | Nycomed Gmbh | Derivados heterociclicos de pirazolona, composiciones farmaceuticas que los contienen y uso de los mismos para el tratamiento de enfermedades de las vias respiratorias. |
WO2010141550A2 (en) * | 2009-06-04 | 2010-12-09 | Wyeth Llc | 11-beta hsd1 inhibitors |
WO2011107494A1 (de) | 2010-03-03 | 2011-09-09 | Sanofi | Neue aromatische glykosidderivate, diese verbindungen enthaltende arzneimittel und deren verwendung |
NZ604035A (en) | 2010-06-04 | 2015-02-27 | Albany Molecular Res Inc | Glycine transporter-1 inhibitors, methods of making them, and uses thereof |
EP2582709B1 (de) | 2010-06-18 | 2018-01-24 | Sanofi | Azolopyridin-3-on-derivate als inhibitoren von lipasen und phospholipasen |
US8530413B2 (en) | 2010-06-21 | 2013-09-10 | Sanofi | Heterocyclically substituted methoxyphenyl derivatives with an oxo group, processes for preparation thereof and use thereof as medicaments |
TW201221505A (en) | 2010-07-05 | 2012-06-01 | Sanofi Sa | Aryloxyalkylene-substituted hydroxyphenylhexynoic acids, process for preparation thereof and use thereof as a medicament |
TW201215387A (en) | 2010-07-05 | 2012-04-16 | Sanofi Aventis | Spirocyclically substituted 1,3-propane dioxide derivatives, processes for preparation thereof and use thereof as a medicament |
TW201215388A (en) | 2010-07-05 | 2012-04-16 | Sanofi Sa | (2-aryloxyacetylamino)phenylpropionic acid derivatives, processes for preparation thereof and use thereof as medicaments |
US8901114B2 (en) | 2011-03-08 | 2014-12-02 | Sanofi | Oxathiazine derivatives substituted with carbocycles or heterocycles, method for producing same, drugs containing said compounds, and use thereof |
EP2683699B1 (de) | 2011-03-08 | 2015-06-24 | Sanofi | Di- und trisubstituierte oxathiazinderivate, verfahren zu deren herstellung, ihre verwendung als medikament sowie sie enthaltendes arzneimittel und deren verwendung |
EP2683704B1 (de) | 2011-03-08 | 2014-12-17 | Sanofi | Verzweigte oxathiazinderivate, verfahren zu deren herstellung, ihre verwendung als medikament sowie sie enthaltendes arzneimittel und deren verwendung |
US8871758B2 (en) | 2011-03-08 | 2014-10-28 | Sanofi | Tetrasubstituted oxathiazine derivatives, method for producing them, their use as medicine and drug containing said derivatives and the use thereof |
WO2012120054A1 (de) | 2011-03-08 | 2012-09-13 | Sanofi | Di- und trisubstituierte oxathiazinderivate, verfahren zu deren herstellung, ihre verwendung als medikament sowie sie enthaltendes arzneimittel und deren verwendung |
CA2837247C (en) * | 2011-07-01 | 2020-03-31 | Remynd Nv | 1 , 2 , 4 -thiadiazol- 5 -ylpiperazine derivatives useful in the treatment neurodegenerative diseases |
WO2013037390A1 (en) | 2011-09-12 | 2013-03-21 | Sanofi | 6-(4-hydroxy-phenyl)-3-styryl-1h-pyrazolo[3,4-b]pyridine-4-carboxylic acid amide derivatives as kinase inhibitors |
WO2013045413A1 (en) | 2011-09-27 | 2013-04-04 | Sanofi | 6-(4-hydroxy-phenyl)-3-alkyl-1h-pyrazolo[3,4-b]pyridine-4-carboxylic acid amide derivatives as kinase inhibitors |
US10092574B2 (en) | 2012-09-26 | 2018-10-09 | Valorisation-Recherche, Limited Partnership | Inhibitors of polynucleotide repeat-associated RNA foci and uses thereof |
TWI659021B (zh) | 2013-10-10 | 2019-05-11 | 亞瑞克西斯製藥公司 | Kras g12c之抑制劑 |
JP6339416B2 (ja) * | 2014-05-28 | 2018-06-06 | 国立大学法人 名古屋工業大学 | 光学活性スルホンアミド誘導体の製造方法 |
CN104974084A (zh) * | 2015-07-19 | 2015-10-14 | 佛山市赛维斯医药科技有限公司 | 一类胺基二吡啶叔醇结构的11β-HSD1抑制剂及其用途 |
EP3235813A1 (en) | 2016-04-19 | 2017-10-25 | Cidqo 2012, S.L. | Aza-tetra-cyclo derivatives |
EP3573964A1 (en) * | 2017-01-26 | 2019-12-04 | Araxes Pharma LLC | Benzothiophene and benzothiazole compounds and methods of use thereof |
WO2018140514A1 (en) | 2017-01-26 | 2018-08-02 | Araxes Pharma Llc | 1-(6-(3-hydroxynaphthalen-1-yl)quinazolin-2-yl)azetidin-1-yl)prop-2-en-1-one derivatives and similar compounds as kras g12c inhibitors for the treatment of cancer |
WO2018140513A1 (en) | 2017-01-26 | 2018-08-02 | Araxes Pharma Llc | 1-(3-(6-(3-hydroxynaphthalen-1-yl)benzofuran-2-yl)azetidin-1yl)prop-2-en-1-one derivatives and similar compounds as kras g12c modulators for treating cancer |
US11274093B2 (en) | 2017-01-26 | 2022-03-15 | Araxes Pharma Llc | Fused bicyclic benzoheteroaromatic compounds and methods of use thereof |
US11639346B2 (en) | 2017-05-25 | 2023-05-02 | Araxes Pharma Llc | Quinazoline derivatives as modulators of mutant KRAS, HRAS or NRAS |
CA3063440A1 (en) | 2017-05-25 | 2018-11-29 | Araxes Pharma Llc | Covalent inhibitors of kras |
GB201713780D0 (en) * | 2017-08-29 | 2017-10-11 | E-Therapeutics Plc | Modulators of hedgehog (Hh) signalling pathway |
AU2019339777B2 (en) | 2018-09-12 | 2022-09-01 | Novartis Ag | Antiviral pyridopyrazinedione compounds |
EP3890715A4 (en) * | 2018-12-04 | 2023-03-29 | The Board Of Regents Of The University Of Texas System | THERAPEUTIC AGENTS TARGETING ADENOMATOCOLIC POLYPOSIS (APC) MUTANT FOR THE TREATMENT OF CANCER |
CN111943893A (zh) * | 2019-05-17 | 2020-11-17 | 南京爱德程医药科技有限公司 | 4,7-二氮杂螺[2.5]辛烷类化合物的合成方法 |
EP3770201B1 (en) * | 2019-07-22 | 2023-05-31 | Evonik Operations GmbH | Polymeric anion-conducting membrane |
TW202126649A (zh) | 2019-09-26 | 2021-07-16 | 瑞士商諾華公司 | 抗病毒吡唑并吡啶酮化合物 |
CN114901640A (zh) * | 2019-12-24 | 2022-08-12 | 兹杜斯生命科学有限公司 | 适用于治疗血脂异常的新型化合物 |
Family Cites Families (62)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US2875205A (en) * | 1959-02-24 | Chj-chj | ||
ZA813332B (en) * | 1980-06-21 | 1982-05-26 | Pfizer | Larvicides and isecticides |
JPS6081168A (ja) * | 1983-10-13 | 1985-05-09 | Asahi Chem Ind Co Ltd | アミジン誘導体 |
FR2553414B1 (fr) | 1983-10-18 | 1986-08-14 | Choay Sa | Nouveaux benzenesulfonamides n-cyclises, leur procede de preparation et leur utilisation comme substance active de compositions pharmaceutiques |
US4857644A (en) | 1988-06-09 | 1989-08-15 | American Home Products Corporation | Aryl sulfonopiperazines as anti-inflammatory agents |
WO1993012086A1 (en) * | 1991-12-11 | 1993-06-24 | Ss Pharmaceutical Co., Ltd. | Arylamide derivative |
EP0661266A1 (en) | 1993-12-27 | 1995-07-05 | Toa Eiyo Ltd. | Substituted cyclic amine compounds as 5HT2 antagonists |
US5464788A (en) | 1994-03-24 | 1995-11-07 | Merck & Co., Inc. | Tocolytic oxytocin receptor antagonists |
CA2249615A1 (en) | 1996-04-03 | 1997-10-09 | Robert Gomez | Inhibitors of farnesyl-protein transferase |
US6063930A (en) | 1996-04-03 | 2000-05-16 | Merck & Co., Inc. | Substituted imidazole compounds useful as farnesyl-protein transferase inhibitors |
AU2802297A (en) | 1996-04-18 | 1997-11-07 | Merck & Co., Inc. | A method of treating cancer |
JP2000508335A (ja) | 1996-05-30 | 2000-07-04 | メルク エンド カンパニー インコーポレーテッド | 癌の治療方法 |
WO1998044797A1 (en) | 1997-04-07 | 1998-10-15 | Merck & Co., Inc. | A method of treating cancer |
US6297239B1 (en) | 1997-10-08 | 2001-10-02 | Merck & Co., Inc. | Inhibitors of prenyl-protein transferase |
AU754529B2 (en) | 1998-09-22 | 2002-11-21 | Yamanouchi Pharmaceutical Co., Ltd. | Cyanophenyl derivatives |
WO2000025789A1 (en) | 1998-10-29 | 2000-05-11 | Merck & Co., Inc. | A method of treating endometriosis |
JP2003525203A (ja) * | 1999-03-22 | 2003-08-26 | ダーウィン・ディスカバリー・リミテッド | ヒドロキサムおよびカルボン酸誘導体 |
WO2001066534A2 (en) | 2000-03-09 | 2001-09-13 | Abbott Laboratories | Cyclic and bicyclic diamino histamine-3 receptor antagonists |
JP2001261657A (ja) | 2000-03-17 | 2001-09-26 | Yamanouchi Pharmaceut Co Ltd | シアノフェニル誘導体 |
JP2001328938A (ja) | 2000-03-17 | 2001-11-27 | Yamanouchi Pharmaceut Co Ltd | シアノフェニル誘導体を有効成分とする医薬 |
ATE311628T1 (de) * | 2000-06-16 | 2005-12-15 | Baumueller Anlagen Systemtech | Verfahren zum automatischen erzeugen mehrerer elektrischer impulse anhand numerischer vorgabewerte, insbesondere als inkrementalgeber- nachbildung |
US7179912B2 (en) | 2000-09-01 | 2007-02-20 | Icos Corporation | Materials and methods to potentiate cancer treatment |
EP1217000A1 (en) | 2000-12-23 | 2002-06-26 | Aventis Pharma Deutschland GmbH | Inhibitors of factor Xa and factor VIIa |
GB0108591D0 (en) | 2001-04-05 | 2001-05-23 | Merck Sharp & Dohme | Therapeutic agents |
GB0120347D0 (en) | 2001-08-21 | 2001-10-17 | Merck Sharp & Dohme | Therapeutic agents |
EA006225B1 (ru) | 2001-08-21 | 2005-10-27 | Мерк Шарп Энд Домэ Лимитед | Новые циклогексилсульфоны |
AU2002353716A1 (en) | 2001-11-22 | 2003-06-10 | Biovitrum Ab | Inhibitors of 11-beta-hydroxy steroid dehydrogenase type 1 |
BR0214342A (pt) | 2001-11-22 | 2004-09-14 | Biovitrum Ab | Inibidores de 11 - beta - hidroxi esteróide desidrogenase tipo 1 |
EP1485365B1 (en) | 2002-03-13 | 2008-05-14 | Janssen Pharmaceutica N.V. | Sulfonyl-derivatives as novel inhibitors of histone deacetylase |
KR20050025189A (ko) | 2002-07-27 | 2005-03-11 | 아스트라제네카 아베 | 화학 화합물 |
US20050256159A1 (en) | 2002-10-11 | 2005-11-17 | Astrazeneca Ab | 1,4-disubstituted piperidine derivatives and their use as 11,betahsd1 inhibitors |
US20060058315A1 (en) | 2002-11-07 | 2006-03-16 | Astrazeneca Ab | 2-Oxo-ethanesulfonamide derivates |
TW200503994A (en) | 2003-01-24 | 2005-02-01 | Novartis Ag | Organic compounds |
WO2004092117A1 (en) | 2003-04-07 | 2004-10-28 | Kalypsys, Inc. | Para-sulfonyl substituted phenyl compounds as modulators of ppars |
WO2004089416A2 (en) * | 2003-04-11 | 2004-10-21 | Novo Nordisk A/S | Combination of an 11beta-hydroxysteroid dehydrogenase type 1 inhibitor and an antihypertensive agent |
WO2004089471A2 (en) | 2003-04-11 | 2004-10-21 | Novo Nordisk A/S | NEW PYRAZOLO[1,5-a] PYRIMIDINES DERIVATIVES AND PHARMACEUTICAL USE THEREOF |
WO2005011654A2 (en) | 2003-07-29 | 2005-02-10 | Xenon Pharmaceuticals Inc. | Pyridyl derivatives and their use as therapeutic agents |
CA2533901A1 (en) | 2003-07-30 | 2005-02-10 | Xenon Pharmaceuticals Inc. | Piperazine derivatives and their use as therapeutic agents |
KR20060036106A (ko) | 2003-07-30 | 2006-04-27 | 제논 파마슈티칼스 인크. | 피리딜 유도체 및 그의 치료제로서의 용도 |
US20050124625A1 (en) | 2003-10-21 | 2005-06-09 | Salvati Mark E. | Piperazine derivatives and their use as modulators of nuclear hormone receptor function |
GB0325956D0 (en) | 2003-11-06 | 2003-12-10 | Addex Pharmaceuticals Sa | Novel compounds |
WO2005063247A1 (en) | 2003-12-22 | 2005-07-14 | Amgen Inc. | Aryl sulfonamide compounds and uses related thereto |
AU2005207925B2 (en) | 2004-01-26 | 2008-09-04 | Merck Sharp & Dohme Corp. | Novel crystalline forms of an inhibitor of 11-beta-hydroxysteroid dehydrogenase Type 1 |
US20050277629A1 (en) | 2004-03-18 | 2005-12-15 | The Brigham And Women's Hospital, Inc. | Methods for the treatment of synucleinopathies (Lansbury) |
AR048523A1 (es) | 2004-04-07 | 2006-05-03 | Kalypsys Inc | Compuestos con estructura de aril sulfonamida y sulfonilo como moduladores de ppar y metodos para tratar trastornos metabolicos |
WO2005110980A2 (en) | 2004-04-14 | 2005-11-24 | Amgen, Inc. | Aryl sulfones and uses related thereto |
ES2390057T3 (es) * | 2004-04-20 | 2012-11-06 | Amgen Inc. | Arilsulfonilamidas y usos como hidroxiesteroide deshidrogenasa |
TWI350168B (en) | 2004-05-07 | 2011-10-11 | Incyte Corp | Amido compounds and their use as pharmaceuticals |
WO2005113542A2 (en) | 2004-05-20 | 2005-12-01 | Elan Pharmaceuticals, Inc. | N-cyclic sulfonamido inhibitors of gamma secretase |
MXPA06014572A (es) | 2004-06-24 | 2007-03-12 | Incyte Corp | Compuestos amido y su uso como farmaceuticos. |
WO2006002350A1 (en) | 2004-06-24 | 2006-01-05 | Incyte Corporation | Amido compounds and their use as pharmaceuticals |
EP1768954A4 (en) | 2004-06-24 | 2008-05-28 | Incyte Corp | 2-METHYLPROPANAMIDES AND THEIR USE AS PHARMACEUTICALS |
AU2005256442B2 (en) | 2004-06-28 | 2009-02-12 | F. Hoffmann-La Roche Ag | Pyrimidine derivatives as 11beta-HSD1 inhibitors |
EP1789404B1 (en) | 2004-06-30 | 2010-03-24 | Schering Corporation | Substituted n-arylsulfonylheterocyclic amines as gamma-secretase inhibitors |
WO2006010546A2 (en) | 2004-07-28 | 2006-02-02 | F. Hoffman-La Roche Ag | Aryl-pyridine derivatives as 11-beta-hsd1 inhibitors |
US20060025445A1 (en) | 2004-08-02 | 2006-02-02 | Xiang Jason S | 11-Beta HSD1 inhibitors |
WO2006048771A1 (en) | 2004-11-04 | 2006-05-11 | Addex Pharmaceuticals Sa | Novel tetrazole derivatives as positive allosteric modulators of metabotropic glutamate receptors |
GB0510143D0 (en) | 2005-05-18 | 2005-06-22 | Addex Pharmaceuticals Sa | Novel compounds A1 |
EP1866298A2 (en) | 2005-03-31 | 2007-12-19 | Takeda San Diego, Inc. | Hydroxysteroid dehydrogenase inhibitors |
JP2009514859A (ja) * | 2005-11-03 | 2009-04-09 | メルク エンド カムパニー インコーポレーテッド | 置換ニコチンアミド化合物 |
CA2632027A1 (en) | 2005-12-14 | 2007-06-21 | Amgen Inc. | Diaza heterocyclic sulfonamide derivatives and their uses |
WO2007075629A2 (en) | 2005-12-21 | 2007-07-05 | Schering Corporation | Phenoxypiperidines and analogs thereof useful as histamine h3 antagonists |
-
2007
- 2007-02-07 BR BRPI0707537-5A patent/BRPI0707537A2/pt not_active IP Right Cessation
- 2007-02-07 PA PA20078713501A patent/PA8713501A1/es unknown
- 2007-02-07 AR ARP070100510A patent/AR059355A1/es unknown
- 2007-02-07 WO PCT/US2007/003134 patent/WO2007092435A2/en active Application Filing
- 2007-02-07 TW TW096104455A patent/TW200800898A/zh unknown
- 2007-02-07 EP EP07717205A patent/EP1981848A2/en not_active Withdrawn
- 2007-02-07 US US11/703,522 patent/US7632838B2/en not_active Expired - Fee Related
- 2007-02-07 RU RU2008132333/04A patent/RU2008132333A/ru not_active Application Discontinuation
- 2007-02-07 CN CNA2007800088400A patent/CN101400653A/zh active Pending
- 2007-02-07 JP JP2008554299A patent/JP2009526059A/ja not_active Withdrawn
- 2007-02-07 KR KR1020087021870A patent/KR20080093072A/ko not_active Application Discontinuation
- 2007-02-07 CA CA002641609A patent/CA2641609A1/en not_active Abandoned
- 2007-02-07 PE PE2007000130A patent/PE20071232A1/es not_active Application Discontinuation
- 2007-02-07 AU AU2007212429A patent/AU2007212429A1/en not_active Abandoned
-
2008
- 2008-07-30 CR CR10186A patent/CR10186A/es not_active Application Discontinuation
- 2008-07-31 IL IL193157A patent/IL193157A0/en unknown
- 2008-08-07 GT GT200800151A patent/GT200800151A/es unknown
- 2008-08-12 NO NO20083492A patent/NO20083492L/no not_active Application Discontinuation
-
2009
- 2009-08-11 US US12/539,232 patent/US20100029648A1/en not_active Abandoned
Also Published As
Publication number | Publication date |
---|---|
KR20080093072A (ko) | 2008-10-17 |
PE20071232A1 (es) | 2008-02-18 |
WO2007092435A2 (en) | 2007-08-16 |
CR10186A (es) | 2008-10-29 |
GT200800151A (es) | 2008-11-03 |
JP2009526059A (ja) | 2009-07-16 |
CA2641609A1 (en) | 2007-08-16 |
NO20083492L (no) | 2008-10-28 |
US7632838B2 (en) | 2009-12-15 |
TW200800898A (en) | 2008-01-01 |
PA8713501A1 (es) | 2009-09-17 |
US20100029648A1 (en) | 2010-02-04 |
US20070219198A1 (en) | 2007-09-20 |
EP1981848A2 (en) | 2008-10-22 |
CN101400653A (zh) | 2009-04-01 |
WO2007092435A3 (en) | 2007-12-27 |
RU2008132333A (ru) | 2010-03-20 |
BRPI0707537A2 (pt) | 2011-05-03 |
IL193157A0 (en) | 2009-02-11 |
AU2007212429A1 (en) | 2007-08-16 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
AR059355A1 (es) | Inhibidores de 11-beta hsd1 | |
AR065276A1 (es) | Herbicidas de n-oxidos de piridina sustituidos | |
RU2016118768A (ru) | Композиции, пригодные для лечения расстройств, связанных с kit | |
CR20130308A (es) | Compuestos y su uso como inhibidores de bace | |
BRPI0610322B8 (pt) | inibidores de sinalização de receptor de vegf e de receptor de hgf e composição farmacêutica | |
BRPI0810199A2 (pt) | Síntese catalisada por metal de transição de n-aminoindóis | |
TN2010000092A1 (en) | Humanized cxcr5 antidodies, derivatives thereof and their uses | |
MA30057B1 (fr) | Nucleosides antiviraux | |
WO2011103175A3 (en) | Oxysterols that activate liver x receptor signaling and inhibit hedgehog signaling | |
MX2009008159A (es) | Compuestos y composiciones como moduladores de la actividad de gpr119. | |
EA200900828A1 (ru) | Соединения и композиции в качестве ингибиторов активности каннабиноидного рецептора 1 | |
MX2010005861A (es) | Agonistas novedosos de los receptores de glucocorticoides. | |
AR085903A1 (es) | Compuestos de pirazol sustituidos con halogeno | |
CA2642211A1 (en) | 2,4-pyrimidinediamine compounds for treating or preventing autoimmune diseases | |
GT200600327A (es) | Ciclohexilaminoisoquinolona | |
TN2009000273A1 (en) | New substituted isoquinoline and isoquinolinone derivatives | |
AR104915A1 (es) | Derivados de 2-(feniloxi o feniltio)pirimidina como herbicidas | |
BR112015029090A8 (pt) | 3,4-dihidroisoquinolin- 2(1h)-ila, seus usos, composição farmacêuticas e sua forma cocristalina | |
EA200970065A1 (ru) | Производные пиперазинила, предназначенные для лечения заболеваний, опосредованных рецептором gpr38 | |
BR112015015515A2 (pt) | composições fungicidas sinérgicas | |
UY30220A1 (es) | Compuestos de tetrahidropiridotienopirimidina y metodos para su empleo | |
MA31776B1 (fr) | Composé inhibiteur de la glycogène phosphorylase et composition pharmaceutique contenant ledit composé | |
ATE533492T1 (de) | Behandlung oder prävention von hypertensiven erkrankungen in der schwangerschaft oder von wachstumsverzögerung des foeten | |
EA201300338A1 (ru) | Пестицидная и паразитицидная смесь и композиция, которая включает новую кристаллическую модификацию фипронила | |
MA32943B1 (fr) | Piperidine spiro pyrrolidione et piperidinone substituees, leur preparation et leur utilisation therapeutique |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
FB | Suspension of granting procedure |